ACADIA Pharmaceuticals Inc (ACAD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)

ACAD 25.04

+0.9%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	11/6/2007 5:23:48 PM
	Read Replies (1) of 588

09:16 am ACADIA Pharmaceuticals: Brean Murray downgrades Hold to Sell . Target $7. Brean Murray downgrades ACAD to Sell from Hold with a $7 tgt based on comments made by management during its most recent quarterly conference call, management's inability to establish a commercial partnership for pimavanserin 10 months following the initial report of Phase 2b top-line results and management's reluctance to speak about such partnership discussions. The firm says they are further led to believe that their original skepticism of a lack of a clearly established efficacy and improved safety profile for pimavanserin in the Phase 2b schizophrenia co-therapy trial is correct. +++++++++++++++++++++++++++++++++++++ Brean Murray Analyst must live in a different universe than I do. I've yet to see any Pharma or Biotech share the desired partnership info in advance of any agreement ever. And most tell us precious little after the fact. And how many Phase II trials have given a clear efficacy signal in the past decade? My guess is fewer than 10.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next